688513 苑东生物
已收盘 12-31 15:00:01
资讯
新帖
简况
苑东生物（688513）披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药，12月30日股价上涨1.7%
证券之星 · 12-30 17:44
苑东生物（688513）披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药，12月30日股价上涨1.7%
每周股票复盘：苑东生物（688513）亚甲蓝注射液获FDA批准
证券之星 · 12-28
每周股票复盘：苑东生物（688513）亚甲蓝注射液获FDA批准
苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准
智通财经 · 12-24
苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准
苑东生物（688513）披露布瑞哌唑片获得药品注册证书，12月10日股价上涨1.75%
证券之星 · 12-10
苑东生物（688513）披露布瑞哌唑片获得药品注册证书，12月10日股价上涨1.75%
苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书
智通财经 · 12-09
苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书
苑东生物最新公告：全资子公司硕德药业通过美国FDA现场检查
证券之星 · 11-27
苑东生物最新公告：全资子公司硕德药业通过美国FDA现场检查
苑东生物：公司会在定期报告中披露相应时点的股东户数
证券日报网 · 11-24
苑东生物：公司会在定期报告中披露相应时点的股东户数
11月19日苑东生物跌5.06%，博时研究优选LOF基金重仓该股
证券之星 · 11-19
11月19日苑东生物跌5.06%，博时研究优选LOF基金重仓该股
每周股票复盘：苑东生物（688513）注射用YLSH003启动I/II期临床
证券之星 · 11-16
每周股票复盘：苑东生物（688513）注射用YLSH003启动I/II期临床
苑东生物（688513）披露自愿披露注射用YLSH003启动I/II期临床试验并完成首例受试者入组，11月11日股价下跌1.36%
证券之星 · 11-11
苑东生物（688513）披露自愿披露注射用YLSH003启动I/II期临床试验并完成首例受试者入组，11月11日股价下跌1.36%
苑东生物(688513.SH)：注射用YLSH003启动I/II期临床试验并完成首例受试者入组
智通财经 · 11-10
苑东生物(688513.SH)：注射用YLSH003启动I/II期临床试验并完成首例受试者入组
每周股票复盘：苑东生物（688513）奥沙西泮片实现首次发货
证券之星 · 11-09
每周股票复盘：苑东生物（688513）奥沙西泮片实现首次发货
11月4日苑东生物跌6.26%，博时研究优选LOF基金重仓该股
证券之星 · 11-04
11月4日苑东生物跌6.26%，博时研究优选LOF基金重仓该股
苑东生物最新公告：拟中选国家组织药品联合采购办公室组织的第十一批全国药品集中采购
证券之星 · 10-28
苑东生物最新公告：拟中选国家组织药品联合采购办公室组织的第十一批全国药品集中采购
图解苑东生物三季报：第三季度单季净利润同比增长18.52%
证券之星 · 10-27
图解苑东生物三季报：第三季度单季净利润同比增长18.52%
苑东生物(688513)9月30日股东户数0.65万户，较上期增加18.67%
证券之星 · 10-27
苑东生物(688513)9月30日股东户数0.65万户，较上期增加18.67%
每周股票复盘：苑东生物（688513）新增赵立文为核心技术人员
证券之星 · 10-19
每周股票复盘：苑东生物（688513）新增赵立文为核心技术人员
苑东生物(688513.SH)：艾拉莫德片获得药品注册证书
智通财经 · 10-17
苑东生物(688513.SH)：艾拉莫德片获得药品注册证书
苑东生物（688513）披露新增认定核心技术人员，10月13日股价上涨0.3%
证券之星 · 10-13
苑东生物（688513）披露新增认定核心技术人员，10月13日股价上涨0.3%
每周股票复盘：苑东生物（688513）取消监事会并选举职工董事
证券之星 · 10-12
每周股票复盘：苑东生物（688513）取消监事会并选举职工董事
加载更多
公司概况
公司名称：
成都苑东生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-09-02
主营业务：
成都苑东生物制药股份有限公司的主营业务是化学原料药、高端化学药品及生物药品研发、生产、销售。公司的主要产品是高端化学药品、创新药、原料药。
发行价格：
44.36
{"stockData":{"symbol":"688513","market":"SH","secType":"STK","nameCN":"苑东生物","latestPrice":61.55,"timestamp":1767164401000,"preClose":60.51,"halted":0,"volume":1579909,"delay":0,"changeRate":0.0172,"floatShares":177000000,"shares":177000000,"eps":1.3674,"marketStatus":"已收盘","change":1.04,"latestTime":"12-31 15:00:01","open":60.3,"high":61.73,"low":59.62,"amount":96431300,"amplitude":0.0349,"askPrice":61.68,"askSize":15,"bidPrice":61.55,"bidSize":11,"shortable":0,"etf":0,"ttmEps":1.3674,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":60.51,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":66.56,"lowLimit":54.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":176532256,"isCdr":false,"pbRate":3.79,"roa":"--","peRate":45.012432,"roe":"7.93%","epsLYR":1.36,"committee":-0.441341,"marketValue":10866000000,"turnoverRate":0.0089,"status":0,"afterMarket":{"amount":0,"volume":0,"close":61.55,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":60.51},"floatMarketCap":10866000000},"requestUrl":"/m/hq/s/688513","defaultTab":"news","newsList":[{"id":"2595881795","title":"苑东生物（688513）披露HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药，12月30日股价上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595881795","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595881795?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:44","pubTimestamp":1767087896,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，苑东生物报收于60.51元，较前一交易日上涨1.7%，最新总市值为106.82亿元。该股当日开盘58.3元，最高61.16元，最低58.3元，成交额达8723.49万元，换手率为0.82%。公司近日发布公告称，控股子公司上海超阳药业自主研发的1类创新药HP-001胶囊联合地塞米松治疗复发难治多发性骨髓瘤的I/II期临床试验已完成首例受试者给药。本次联合用药临床试验旨在评估其在复发难治多发性骨髓瘤患者中的安全性、耐受性、药代动力学及疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2594826247","title":"每周股票复盘：苑东生物（688513）亚甲蓝注射液获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2594826247","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594826247?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:47","pubTimestamp":1766868426,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，苑东生物报收于59.95元，较上周的57.28元上涨4.66%。本周，苑东生物12月26日盘中最高价报60.39元。本周关注点公司公告汇总：亚甲蓝注射液获得美国FDA药品注册批准，ANDA号219550。公司公告汇总苑东生物：关于自愿披露亚甲蓝注射液获得美国FDA药品注册批准的公告成都苑东生物制药股份有限公司全资子公司成都硕德药业有限公司收到美国FDA通知，其申报的亚甲蓝注射液简化新药申请获得批准，ANDA号219550，规格50mg/10mL。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2593784084","title":"苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593784084","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593784084?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:00","pubTimestamp":1766566836,"startTime":"0","endTime":"0","summary":"智通财经APP讯，苑东生物(688513.SH)发布公告，公司全资子公司成都硕德药业有限公司(简称“硕德药业”)于近日收到美国食品药品监督管理局(简称“美国FDA”)的通知，硕德药业向美国FDA申报的亚甲蓝注射液的简化新药申请(ANDA，即美国仿制药申请)获得正式批准。亚甲蓝注射液的活性成分为亚甲蓝，适应症为用于治疗儿童和成人获得性高铁血红蛋白血症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"苑东生物(688513.SH)：亚甲蓝注射液获得美国FDA药品注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2590913583","title":"苑东生物（688513）披露布瑞哌唑片获得药品注册证书，12月10日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590913583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590913583?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:51","pubTimestamp":1765360285,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，苑东生物报收于56.35元，较前一交易日上涨1.75%，最新总市值为99.48亿元。该股当日开盘55.38元，最高56.58元，最低54.75元，成交额达4341.98万元，换手率为0.44%。公司近日发布公告称，成都苑东生物制药股份有限公司收到国家药品监督管理局核准签发的布瑞哌唑片药品注册证书，批准其生产1mg、2mg、4mg规格的布瑞哌唑片，注册分类为化学药品4类，视同通过一致性评价。公告显示，该产品2025年上半年销售额较低，对公司近期业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000028968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2590831173","title":"苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590831173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590831173?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:32","pubTimestamp":1765272750,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 苑东生物(688513.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的《药品注册证书》。布瑞哌唑片活性成分为布瑞哌唑，适应症为用于治疗成人精神分裂症。布瑞哌唑片最早由日本大冢制药(Otsuka Pharmaceutical Co.，Ltd.)开发，于2015年7月在美国获批上市，商品名为Rexulti®，于2024年6月进口中国。国家药监局官网显示，该产品国内目前仅有进口原研药上市，公司该药品是国内首家按新注册分类获批的仿制药，视同通过一致性评价","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2586246064","title":"苑东生物最新公告：全资子公司硕德药业通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2586246064","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586246064?lang=zh_cn&edition=full","pubTime":"2025-11-27 17:50","pubTimestamp":1764237029,"startTime":"0","endTime":"0","summary":"苑东生物(688513.SH)公告称，公司全资子公司硕德药业于2025年5月接受了美国FDA的现行药品生产质量管理规范（cGMP）和生物研究监测（BIMO）现场检查，涉及产品为盐酸纳洛酮鼻喷剂。近日，硕德药业收到FDA出具的两份现场检查报告，以零缺陷通过上述现场检查。此次检查通过有利于加快公司已申报美国ANDA产品的获批进度，但短期内对公司经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700026552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2585931434","title":"苑东生物：公司会在定期报告中披露相应时点的股东户数","url":"https://stock-news.laohu8.com/highlight/detail?id=2585931434","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585931434?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:08","pubTimestamp":1763993280,"startTime":"0","endTime":"0","summary":"证券日报网讯苑东生物11月24日在互动平台回答投资者提问时表示，公司会在定期报告中披露相应时点的股东户数。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-24/doc-infypnsu4817611.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-24/doc-infypnsu4817611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2584396915","title":"11月19日苑东生物跌5.06%，博时研究优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584396915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584396915?lang=zh_cn&edition=full","pubTime":"2025-11-19 15:49","pubTimestamp":1763538543,"startTime":"0","endTime":"0","summary":"证券之星消息，11月19日苑东生物跌5.06%，收盘报53.28元，换手率0.87%，成交量1.53万手，成交额8263.76万元。重仓苑东生物的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为博时基金的博时研究优选LOF。博时研究优选LOF目前规模为9.08亿元，最新净值1.0186，较上一交易日下跌3.9%，近一年上涨33.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900021494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","160916","688513"],"gpt_icon":0},{"id":"2583261651","title":"每周股票复盘：苑东生物（688513）注射用YLSH003启动I/II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2583261651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583261651?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:54","pubTimestamp":1763236454,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，苑东生物报收于56.61元，较上周的55.32元上涨2.33%。本周关注点公司公告汇总：注射用YLSH003启动I/II期临床试验并完成首例受试者入组。注射用YLSH003已于2025年9月获得国家药监局临床试验批准，正在推进受试者招募。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2582354421","title":"苑东生物（688513）披露自愿披露注射用YLSH003启动I/II期临床试验并完成首例受试者入组，11月11日股价下跌1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582354421","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582354421?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:27","pubTimestamp":1762853262,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，苑东生物报收于54.45元，较前一交易日下跌1.36%，最新总市值为96.12亿元。该股当日开盘55.2元，最高55.45元，最低54.21元，成交额达3113.34万元，换手率为0.32%。公司于近日发布公告称，其全资子公司优洛生物（上海）有限公司自主研发的1类生物药注射用YLSH003，近日启动用于晚期实体瘤的I/II期临床试验，并完成首例受试者入组给药。公司已提交1项国际专利申请。注射用YLSH003已于2025年9月获得国家药监局临床试验批准，正在推进受试者招募。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100028367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2582284077","title":"苑东生物(688513.SH)：注射用YLSH003启动I/II期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2582284077","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582284077?lang=zh_cn&edition=full","pubTime":"2025-11-10 15:40","pubTimestamp":1762760456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，苑东生物(688513.SH)发布公告，公司全资子公司优洛生物(上海)有限公司(简称“上海优洛”)自主研发的1类生物药注射用YLSH003正在开展用于晚期实体瘤的I/II期临床试验，首例受试者已于近日成功入组给药。注射用YLSH003是一种靶向组织因子(Tissue Factor，TF)的新型抗体偶联药物(antibody-drug conjugate，ADC)，拟开发用于晚期实体肿瘤治疗。TF是一种跨膜糖蛋白，在生理情况下，是体内凝血过程的主要启动因子。研究表明，肿瘤发生进展时伴随TF高表达是大多数实体肿瘤中后期发生复发和转移的主要原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2582329869","title":"每周股票复盘：苑东生物（688513）奥沙西泮片实现首次发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2582329869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582329869?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:29","pubTimestamp":1762626551,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，苑东生物报收于55.32元，较上周的59.45元下跌6.95%。本周，苑东生物11月3日盘中最高价报62.62元。本周关注点来自机构调研要点：奥沙西泮片已于2025年9月实现首次发货来自机构调研要点：阿帕他胺片已授权覆盖中东、南美、东南亚等12个国家/地区来自机构调研要点：截至2025年9月30日，公司普通股股东总数为6482户机构调研要点问：袁总你好!截至2025年9月30日,公司的普通股股东总数为6482户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2580788617","title":"11月4日苑东生物跌6.26%，博时研究优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788617?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:29","pubTimestamp":1762244991,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日苑东生物跌6.26%，收盘报56.11元，换手率1.52%，成交量2.69万手，成交额1.53亿元。重仓苑东生物的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为博时基金的博时研究优选LOF。博时研究优选LOF目前规模为9.08亿元，最新净值1.0553，较上一交易日上涨1.09%，近一年上涨37.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["160916","BK0239","688513"],"gpt_icon":0},{"id":"2578313979","title":"苑东生物最新公告：拟中选国家组织药品联合采购办公室组织的第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2578313979","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578313979?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:47","pubTimestamp":1761644851,"startTime":"0","endTime":"0","summary":"苑东生物(688513.SH)公告称，公司于2025年10月27日参加了国家组织药品联合采购办公室组织的第十一批全国药品集中采购的投标工作，公司盐酸去氧肾上腺素注射液、贝前列素钠片2个产品拟中选本次集中采购。本次中选产品将在2026年第一季度开始执行，对公司2025年度的经营业绩不会有影响。本次中选价格与原销售价格相比有一定程度下降，若公司后续签订采购合同并实施后，将有利于上述产品提高药品可及性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800032868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2578617548","title":"图解苑东生物三季报：第三季度单季净利润同比增长18.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578617548","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578617548?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:42","pubTimestamp":1761561732,"startTime":"0","endTime":"0","summary":"证券之星消息，苑东生物2025年三季报显示，公司主营收入10.19亿元，同比下降2.0%；归母净利润2.2亿元，同比上升1.45%；扣非净利润1.73亿元，同比上升3.1%；其中2025年第三季度，公司单季度主营收入3.65亿元，同比下降1.55%；单季度归母净利润8359.06万元，同比上升18.52%；单季度扣非净利润6918.61万元，同比上升27.85%；负债率19.47%，投资收益249.7万元，财务费用-474.82万元，毛利率75.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700028934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513"],"gpt_icon":0},{"id":"2578616698","title":"苑东生物(688513)9月30日股东户数0.65万户，较上期增加18.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578616698","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578616698?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:10","pubTimestamp":1761556223,"startTime":"0","endTime":"0","summary":"证券之星消息，近日苑东生物披露，截至2025年9月30日公司股东户数为6482.0户，较6月30日增加1020.0户，增幅为18.67%。户均持股数量由上期的3.23万股减少至2.72万股，户均持股市值为150.71万元。在化学制药行业个股中，苑东生物股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.26万户。根据统计，苑东生物2025年6月30日至2025年9月30日，主力资金净流入1.08亿元，游资资金净流入2634.51万元，散户资金净流出1.34亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700023093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2576335044","title":"每周股票复盘：苑东生物（688513）新增赵立文为核心技术人员","url":"https://stock-news.laohu8.com/highlight/detail?id=2576335044","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576335044?lang=zh_cn&edition=full","pubTime":"2025-10-19 05:02","pubTimestamp":1760821335,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，苑东生物报收于53.88元，较上周的53.08元上涨1.51%。本周，苑东生物10月17日盘中最高价报57.45元。苑东生物当前最新总市值95.12亿元，在化学制药板块市值排名58/150，在两市A股市值排名1895/5158。本周关注点公司公告汇总：苑东生物新增认定赵立文先生为公司核心技术人员。本次变动后，公司核心技术人员为关正品、陈艳、金明志、乔智涛、李竹石、赵立文。公司表示此举有助于提升创新能力，推进创新转型战略实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900001096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2576805040","title":"苑东生物(688513.SH)：艾拉莫德片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2576805040","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576805040?lang=zh_cn&edition=full","pubTime":"2025-10-17 17:09","pubTimestamp":1760692180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，苑东生物(688513.SH)艾拉莫德片获得药品注册证书发布公告，公司全资子公司成都硕德药业有限公司(以下简称“硕德药业”)于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的《药品注册证书》，涉及药品：“艾拉莫德片”。艾拉莫德片活性成分为艾拉莫德，适应症为活动性类风湿关节炎。艾拉莫德片属于《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》乙类品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"苑东生物(688513.SH)：艾拉莫德片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2575471144","title":"苑东生物（688513）披露新增认定核心技术人员，10月13日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575471144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575471144?lang=zh_cn&edition=full","pubTime":"2025-10-13 17:31","pubTimestamp":1760347898,"startTime":"0","endTime":"0","summary":"截至2025年10月13日收盘，苑东生物报收于53.24元，较前一交易日上涨0.3%，最新总市值为93.99亿元。该股当日开盘51.98元，最高53.97元，最低51.14元，成交额达7163.81万元，换手率为0.76%。公告称，公司于2025年10月13日召开第四届董事会第九次会议，审议通过《关于新增认定核心技术人员的议案》，新增认定赵立文先生为公司核心技术人员。本次变动后，公司核心技术人员为关正品、陈艳、金明志、乔智涛、李竹石、赵立文。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300020382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2574468524","title":"每周股票复盘：苑东生物（688513）取消监事会并选举职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2574468524","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574468524?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:09","pubTimestamp":1760209753,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，苑东生物报收于53.08元，较上周的55.34元下跌4.08%。成都苑东生物制药股份有限公司于2025年10月9日召开2025年第二次临时股东大会，审议通过取消监事会、修订《公司章程》并办理工商变更登记的议案。伯小芹女士原为非独立董事，本次选举后变更为职工代表董事，其任期自职工代表大会通过之日起至第四届董事会任期届满。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767178003099,"stockEarnings":[{"period":"1week","weight":0.0291},{"period":"1month","weight":0.1231},{"period":"3month","weight":0.0934},{"period":"6month","weight":0.4221},{"period":"1year","weight":0.9949},{"period":"ytd","weight":1.0274}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都苑东生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6482人(较上一季度增加18.67%)","perCapita":"27234股","listingDate":"2020-09-02","address":"四川省成都市郫都区高新区西源大道8号","registeredCapital":"17653万元","survey":" 成都苑东生物制药股份有限公司的主营业务是化学原料药、高端化学药品及生物药品研发、生产、销售。公司的主要产品是高端化学药品、创新药、原料药。","listedPrice":44.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供苑东生物(688513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"苑东生物,688513,苑东生物股票,苑东生物股票老虎,苑东生物股票老虎国际,苑东生物行情,苑东生物股票行情,苑东生物股价,苑东生物股市,苑东生物股票价格,苑东生物股票交易,苑东生物股票购买,苑东生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供苑东生物(688513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}